Medivolve should trade on revenue numbers & projected EBTIDA I think calculating total revenue is better compared to per testing site share price. We can take numbers from the Medivolve official press release, which is a field with Sedar.
Calculating share price based on per testing site is hard to get the right numbers. Here is an example:
95 test per day per site x$95 per test 95x95=$9025 per day, $270,750 per month, and $3,249,000 per year, then convert this $3,249,000x1.27 to Canadian $4,126,230 per year. Once, we apply 55% EBTIDA $2,269,426. Now, with new outstanding shares after a $5 private placement, 170 million shares. Per-share, EBTIDA comes to 0.0133 per testing site, and now you can apply a PE Ratio of 2 to 5, which is very reasonable. If you use a PE Ratio of two per testing site share price should be $0.0266, and with five, it should be $0.0667 per testing site.
I think calculating revenue and EBTIDA is much better rather than predicting share price. Medivolve is not a speculation play anymore. Medivolve should trade on revenue numbers and projected EBTIDA calculations.